Cannabidiol's Neuroprotective Properties and Potential Treatment of Traumatic Brain Injuries

Overview

Journal Front Neurol

Specialty Neurology

Date 2023 Feb 23

PMID 36816569

Authors

Mackenzie M Aychman

David L Goldman

Joshua S Kaplan

Affiliations

Soon will be listed here.

Abstract

Cannabidiol (CBD) has numerous pharmacological targets that initiate anti-inflammatory, antioxidative, and antiepileptic properties. These neuroprotective benefits have generated interest in CBD's therapeutic potential against the secondary injury cascade from traumatic brain injury (TBI). There are currently no effective broad treatment strategies for combating the damaging mechanisms that follow the primary injury and lead to lasting neurological consequences or death. However, CBD's effects on different neurotransmitter systems, the blood brain barrier, oxidative stress mechanisms, and the inflammatory response provides mechanistic support for CBD's clinical utility in TBI. This review describes the cascades of damage caused by TBI and CBD's neuroprotective mechanisms to counter them. We also present challenges in the clinical treatment of TBI and discuss important future clinical research directions for integrating CBD in treatment protocols. The mechanistic evidence provided by pre-clinical research shows great potential for CBD as a much-needed improvement in the clinical treatment of TBI. Upcoming clinical trials sponsored by major professional sport leagues are the first attempts to test the efficacy of CBD in head injury treatment protocols and highlight the need for further clinical research.

Citing Articles

Cannabinoids for the Treatment of Glaucoma: A Review.

Joshi N, Mariam H, Kamath A Med Cannabis Cannabinoids. 2024; 7(1):183-192.

PMID: 39474241 PMC: 11521503. DOI: 10.1159/000541461.

Pharmacological and physiological effects of cannabidiol: a dose escalation, placebo washout study protocol.

Neary J, Singh J, Alcorn J, Laprairie R, Dehghani P, Mang C BMC Neurol. 2024; 24(1):340.

PMID: 39266961 PMC: 11391713. DOI: 10.1186/s12883-024-03847-1.

Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders.

Bala K, Porel P, Aran K Psychopharmacology (Berl). 2024; 241(10):1939-1954.

PMID: 39264450 DOI: 10.1007/s00213-024-06683-w.

Exosomes derived from microglia overexpressing miR-124-3p alleviate neuronal endoplasmic reticulum stress damage after repetitive mild traumatic brain injury.

Wang Y, Li D, Zhang L, Yin Z, Han Z, Ge X Neural Regen Res. 2024; 19(9):2010-2018.

PMID: 38227530 PMC: 11040294. DOI: 10.4103/1673-5374.391189.

Alzheimer's disease, aging, and cannabidiol treatment: a promising path to promote brain health and delay aging.

Liu Y Mol Biol Rep. 2024; 51(1):121.

PMID: 38227160 DOI: 10.1007/s11033-023-09162-1.

References

Hardingham G, Fukunaga Y, Bading H . Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002; 5(5):405-14. DOI: 10.1038/nn835. View

Kelly D, Martin N, Kordestani R, Counelis G, Hovda D, Bergsneider M . Cerebral blood flow as a predictor of outcome following traumatic brain injury. J Neurosurg. 1997; 86(4):633-41. DOI: 10.3171/jns.1997.86.4.0633. View

Katz P, Sulzer J, Impastato R, Teng S, Rogers E, Molina P . Endocannabinoid degradation inhibition improves neurobehavioral function, blood-brain barrier integrity, and neuroinflammation following mild traumatic brain injury. J Neurotrauma. 2014; 32(5):297-306. PMC: 4348366. DOI: 10.1089/neu.2014.3508. View

Stamatovic S, Dimitrijevic O, Keep R, Andjelkovic A . Inflammation and brain edema: new insights into the role of chemokines and their receptors. Acta Neurochir Suppl. 2006; 96:444-50. DOI: 10.1007/3-211-30714-1_91. View

Ikonomidou C, Turski L . Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury?. Lancet Neurol. 2003; 1(6):383-6. DOI: 10.1016/s1474-4422(02)00164-3. View

Williams S, Undieh A . Dopamine D1-like receptor activation induces brain-derived neurotrophic factor protein expression. Neuroreport. 2009; 20(6):606-10. PMC: 2834182. DOI: 10.1097/WNR.0b013e32832a0a98. View

Tjolsen A, Berge O, Hunskaar S, Rosland J, Hole K . The formalin test: an evaluation of the method. Pain. 1992; 51(1):5-17. DOI: 10.1016/0304-3959(92)90003-T. View

Ngwenya L, Danzer S . Impact of Traumatic Brain Injury on Neurogenesis. Front Neurosci. 2019; 12:1014. PMC: 6333744. DOI: 10.3389/fnins.2018.01014. View

McKee A, Daneshvar D . The neuropathology of traumatic brain injury. Handb Clin Neurol. 2015; 127:45-66. PMC: 4694720. DOI: 10.1016/B978-0-444-52892-6.00004-0. View

10.

Raible D, Frey L, Cruz Del Angel Y, Carlsen J, Hund D, Russek S . JAK/STAT pathway regulation of GABAA receptor expression after differing severities of experimental TBI. Exp Neurol. 2015; 271:445-56. PMC: 5969808. DOI: 10.1016/j.expneurol.2015.07.001. View

11.

van Landeghem F, Weiss T, Oehmichen M, von Deimling A . Decreased expression of glutamate transporters in astrocytes after human traumatic brain injury. J Neurotrauma. 2006; 23(10):1518-28. DOI: 10.1089/neu.2006.23.1518. View

12.

Pretzsch C, Voinescu B, Mendez M, Wichers R, Ajram L, Ivin G . The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD). J Psychopharmacol. 2019; 33(9):1141-1148. PMC: 6732821. DOI: 10.1177/0269881119858306. View

13.

Yeisley D, Arabiyat A, Hahn M . Cannabidiol-Driven Alterations to Inflammatory Protein Landscape of Lipopolysaccharide-Activated Macrophages May Be Mediated by Autophagy and Oxidative Stress. Cannabis Cannabinoid Res. 2021; 6(3):253-263. PMC: 8217602. DOI: 10.1089/can.2020.0109. View

14.

Jenkins P, Mehta M, Sharp D . Catecholamines and cognition after traumatic brain injury. Brain. 2016; 139(Pt 9):2345-71. PMC: 4995357. DOI: 10.1093/brain/aww128. View

15.

Mackie K . Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008; 20 Suppl 1:10-4. DOI: 10.1111/j.1365-2826.2008.01671.x. View

16.

Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M . Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem. 2007; 102(5):1488-1496. DOI: 10.1111/j.1471-4159.2007.04565.x. View

17.

Roberts D, Hu Y, Lund I, Brooks-Kayal A, Russek S . Brain-derived neurotrophic factor (BDNF)-induced synthesis of early growth response factor 3 (Egr3) controls the levels of type A GABA receptor alpha 4 subunits in hippocampal neurons. J Biol Chem. 2006; 281(40):29431-5. DOI: 10.1074/jbc.C600167200. View

18.

Guerriero R, Giza C, Rotenberg A . Glutamate and GABA imbalance following traumatic brain injury. Curr Neurol Neurosci Rep. 2015; 15(5):27. PMC: 4640931. DOI: 10.1007/s11910-015-0545-1. View

19.

Pandelides Z, Aluru N, Thornton C, Watts H, Willett K . Transcriptomic Changes and the Roles of Cannabinoid Receptors and PPARγ in Developmental Toxicities Following Exposure to Δ9-Tetrahydrocannabinol and Cannabidiol. Toxicol Sci. 2021; 182(1):44-59. PMC: 8285010. DOI: 10.1093/toxsci/kfab046. View

20.

Mori M, Meyer E, Soares L, Milani H, Guimaraes F, de Oliveira R . Cannabidiol reduces neuroinflammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 75:94-105. DOI: 10.1016/j.pnpbp.2016.11.005. View